View Older Stories View More Recent Stories
-
Goldman Sachs Downgrades Moderna (MRNA) to Neutral
-
Moderna stock rises following RFK Jr's comments
-
Moderna (MRNA) Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
-
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
-
Moderna Announces Updates on Pandemic Influenza Program
-
Moderna (MRNA) Awarded $590M for Bird Flu Vaccine Development - Reuters
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Moderna (MRNA) updates 2025 expected revenue range to $1.5 to 2.5 billion
-
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
-
Bernstein SocGen Group Reiterates Market Perform Rating on Moderna (MRNA) as Stock Hikes
-
Moderna (MRNA) call put ratio 5.1 calls to 1 put as share price up 12.5%
-
Moderna (MRNA) CEO Issues Letter to Shareholders
-
Argus Downgrades Moderna (MRNA) to Hold
-
Palantir (PLTR), MicroStrategy (MSTR), and Axon (AXON) to join NASDAQ 100
-
Palantir (PLTR), Microstrategy, Inc. (MSTR) Likely to Join Nasdaq 100 as Moderna (MRNA) Exists - Bloomberg Intelligence
-
Could Moderna stock be due for rally in 2025? Jefferies weighs in
-
Carisma Therapeutics (CARM) plans reduction in the workforce by 34%
-
Leerink Partners Cautious on Moderna (MRNA): 'Tick Tick Tick – Getting More Cautious on CMV as Timelines Drag on'
-
Moderna to Present at Upcoming Conferences in December 2024
-
Moderna (MRNA) +9% as Jefferies says the market is nearing short term 'peak RFK negativity'
-
Berenberg Starts Moderna (MRNA) at Hold
-
Moderna (MRNA) PT Lowered to $69 at Piper Sandler
-
Moderna (MRNA) call put ratio 1 call to 6 puts
-
Moderna (MRNA), Others on Watch Following Report Trump Expected to Select Robert F. Kennedy Jr. to lead HHS
-
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
-
Moderna (MRNA) Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
-
Carisma Therapeutics (CARM) Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
-
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
-
Moderna (MRNA) PT Lowered to $55 at TD Cowen
-
Moderna (MRNA) Tops Q3 EPS by 195c
-
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
Bancel To Step Down As Moderna (MRNA) Chief Commercial Officer - Bloomberg
-
Moderna to Present at Upcoming Conferences in November 2024
-
Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
-
Moderna Named a Top Employer by Science for Tenth Consecutive Year
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
-
Northwestern University Files Patent Infringement Lawsuit Against Moderna (MRNA) Over mRNA Vaccine Technologies
-
TD Cowen Reiterates Hold Rating on Moderna (MRNA)
-
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
-
GSK (GSK) Sues Moderna (MRNA) for US Patent Infringement Over MRNA Technology in Covid-19 Vaccines - Court Filing
-
Moderna (MRNA) PT Lowered to $55 at Jefferies
-
Moderna (MRNA) Appoints Abbas Hussain to its Board
-
Abbas Hussain Joins Moderna's Board of Directors
-
Moderna (MRNA) and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan
-
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
-
Moderna (MRNA) Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
-
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
-
Moderna (MRNA) Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant
-
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
-
5 takeaways from Moderna's investor day

